12 hours ago
Tuesday, August 23, 2011
Tech Spotlight: Peptides for Modulating T-Cell Activity, for Treatment of Inflammation and Autoimmune Disease
A University of Colorado research group lead by David Wagner has developed a novel method for modulating autoimmune inflammation by directly impacting the primary cells responsible for the destructive inflammation. This product is a small peptide that has been shown to prevent type I diabetes in the animal disease model; and to reverse hyperglycemia in new-onset mice. Extensive study based on size and composition of the peptide has indicated lead candidates for drug development; Dr. Wagner's work also enables monitoring of treat efficacy.
To read a non-confidential summary of this technology, including links to relevant patent and scientific documents, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.